Medical Condition News

RSS

Diagnosis is vital to differentiae Lewy body dementia and Parkinson's disease dementia

Alzheimer's disease is not the only type of dementia. Two particular forms are dementia with Lewy bodies and Parkinson's disease dementia. In both forms, the diagnosis is of vital importance because the treatment for these dementias differs from that for Alzheimer's dementia, as Brit Mollenhauer and co-authors explain in the dementia theme issue of Deutsches -rzteblatt International.

18 Oct 2010

TOPS program helps in losing weight: Study

In the battle against obesity, new research has found that it may not be necessary to spend a lot on a weight loss program when cheaper, nonprofit alternatives may work just as well.

18 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Hands only CPR effective: New guidelines

According to latest changes made to CPR guidelines rescuers need to start with hard, fast chest presses before giving mouth-to-mouth. The change is termed as “the simplest step first” for traditional CPR, said Dr Michael Sayre, an emergency doctor at Ohio State University Medical Centre and co-author of the guidelines issued by the American Heart Association.

17 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

New rates and benefits for 2011 from APWU Health Plan

APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.

15 Oct 2010

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

Few Americans plan for Alzheimer's despite rise in awareness

A growing number of Americans report knowing a relative or friend afflicted with Alzheimer's, according to a national poll conducted by the public opinion research firm Abt SRBI. Yet despite this rise in awareness, often accompanied by significant anxiety about one day getting this fatal brain disease, few Americans are planning for its eventuality.

15 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

Medtronic CoreValve System IDE for transcatheter aortic valve implantation receives FDA approval

Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) conditional approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol to begin evaluating the Medtronic CoreValve System for transcatheter aortic valve implantation (TAVI).

15 Oct 2010

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.

15 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

AstraZeneca launches new campaign on depression through Facebook and Twitter

AstraZeneca is launching a new campaign called "Take on Depression" through a "Take on Depression" Facebook page and a @FaceDepression Twitter feed to support, educate, and inspire those affected by bipolar depression and major depressive disorder (MDD), also known as depression.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

$Spinal fractures remain undiagnosed and untreated$

Spinal fractures remain undiagnosed and untreated

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

15 Oct 2010

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for the generic versions of Hyzaar® Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar® Tablets, 25 mg, 50 mg and 100 mg, both antihypertensives.

15 Oct 2010

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

Discovery Laboratories, Inc. today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has completed and the results from the study will be presented at the upcoming North American Cystic Fibrosis Conference (NACFC; October 21-23, 2010).

15 Oct 2010

Medical Condition News

Diagnosis is vital to differentiae Lewy body dementia and Parkinson's disease dementia

TOPS program helps in losing weight: Study

Teva Pharmaceutical announces new data from PreCISe study

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Hands only CPR effective: New guidelines

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

New rates and benefits for 2011 from APWU Health Plan

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Few Americans plan for Alzheimer's despite rise in awareness

Access receives first MuGard prescriptions and reimbursement

Medtronic CoreValve System IDE for transcatheter aortic valve implantation receives FDA approval

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Pericytes regulate blood-brain barrier

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

AstraZeneca launches new campaign on depression through Facebook and Twitter

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Spinal fractures remain undiagnosed and untreated

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News